Life Sciences
mRNA Synthesis Considerations for Vaccine and Therapeutic Development
In this GEN webinar, sponsored by Thermo Fisher Scientific, our guest speaker will address the key considerations for mRNA synthesis that help accelerate…
Broadcast Date: December 9, 2022
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
In developing and manufacturing mRNA vaccines and therapeutics, selecting and using the appropriate quality or grade of mRNA raw materials can help you meet critical process, scale, quality, and regulatory needs. Process optimization and risk assessment will also help produce high-quality, high-yield mRNA consistently at scale while minimizing production time and cost.
In this GEN webinar, our guest speaker will address the key considerations for mRNA synthesis that help accelerate the development of mRNA vaccines and therapeutics. Moreover, we will learn about the importance of raw material selection for mRNA synthesis and discuss the scale-up of mRNA production for process development and commercialization. This information will feed into a comprehensive review of mRNA vaccine and therapeutic development workflows.
A live Q&A session will follow the presentation, offering you a chance to pose questions to our expert panelist.
Produced with support from:
Field Applications Scientist
Nucleic Acid Therapeutics
Thermo Fisher Scientific
The post mRNA Synthesis Considerations for Vaccine and Therapeutic Development appeared first on GEN – Genetic Engineering and Biotechnology News.
Wittiest stocks:: Avalo Therapeutics Inc (NASDAQ:AVTX 0.00%), Nokia Corp ADR (NYSE:NOK 0.90%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Spellbinding stocks: LumiraDx Limited (NASDAQ:LMDX 4.62%), Transocean Ltd (NYSE:RIG -2.67%)
There are two main reasons why moving averages are useful in forex trading: moving averages help traders define trend recognize changes in trend. Now well…
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
